卫宁健康(300253) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥689,572,755.63, a decrease of 2.76% compared to the same period last year[2]. - Net profit attributable to shareholders was ¥124,462,452.36, down 8.31% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥120,844,586.98, a decrease of 10.25% compared to the previous year[2]. - In the first three quarters of 2024, the company achieved operating revenue of CNY 1,913.32 million, a year-on-year increase of 0.65%[16]. - The net profit attributable to shareholders was CNY 154.63 million, reflecting a year-on-year growth of 1.51%[16]. - The net profit after deducting non-recurring gains and losses was CNY 142.32 million, up 58.95% year-on-year[16]. - The company's total comprehensive income for the period was CNY 137,443,786.79, compared to CNY 110,774,511.21 in the previous period, reflecting an increase of approximately 24%[25]. - Basic earnings per share increased to CNY 0.0716 from CNY 0.0709, representing a growth of about 0.98%[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,572,926,033.38, reflecting a 0.28% increase from the end of the previous year[2]. - The company's total assets increased to CNY 8,572,926,033.38 from CNY 8,548,945,570.58, showing a growth of approximately 0.28%[22]. - The total liabilities decreased to CNY 2,676,434,913.22 from CNY 2,867,668,499.40, a reduction of about 6.66%[22]. - The equity attributable to shareholders of the parent company rose to CNY 5,897,472,992.97 from CNY 5,687,089,041.72, an increase of approximately 3.69%[22]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥104,007,374.13, a significant improvement of 59.73% compared to the same period last year[2]. - The company reported a significant increase in cash flow from operating activities, contributing to improved liquidity[24]. - Cash inflow from operating activities totaled CNY 2,082,512,492.07, up from CNY 1,865,149,195.50, indicating an increase of approximately 11.6%[26]. - Cash outflow from operating activities was CNY 2,186,519,866.20, compared to CNY 2,123,408,276.67 in the previous period, showing an increase of about 3%[26]. - The net cash flow from operating activities was negative at CNY -104,007,374.13, an improvement from CNY -258,259,081.17 in the previous period[26]. - Cash inflow from investing activities was CNY 2,921,422.89, significantly lower than CNY 79,450,820.24 in the previous period[27]. - Cash outflow from investing activities totaled CNY 226,716,504.74, down from CNY 238,603,434.05, reflecting a decrease of about 5%[27]. - The net cash flow from investing activities was negative at CNY -223,795,081.85, worsening from CNY -159,152,613.81 in the previous period[27]. - Cash inflow from financing activities was CNY 104,062,348.54, compared to CNY 59,392,367.75 in the previous period, indicating an increase of approximately 75%[27]. - The ending cash and cash equivalents balance was CNY 686,882,894.56, slightly up from CNY 668,646,915.85 in the previous period[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 76,136[10]. - The top shareholder, Zhou Wei, holds 8.17% of the shares, amounting to 176,474,241 shares[10]. - The second-largest shareholder, Wang Ying, owns 4.93% of the shares, totaling 106,529,129 shares[10]. - The total shares held by the top ten shareholders account for 19.61% of the company's total equity[12]. - The company has a total of 423,802,370 shares held by Zhou Wei, Wang Ying, Zhou Cheng, and ten private equity products, representing 19.61% of the total shares[12]. - The private equity products managed by Shanghai Ying Shui Investment Management hold a combined total of 77,749,000 shares, which is 3.60% of the total equity[12]. - The total shares held by Liu Ning and associated private equity products amount to 140,627,616 shares, representing 6.51% of the total equity[12]. - The company has not disclosed any relationships or agreements among other shareholders[12]. - The report indicates that there are no changes in the status of pledged, marked, or frozen shares for the top shareholders[10]. Development and Investment - The company reported a 62.30% increase in development expenditures, indicating a focus on project development[7]. - The company plans to expand its market presence and invest in new technologies to enhance its product offerings in the upcoming quarters[24]. - Investment income decreased by 252.50% year-on-year, primarily due to significant gains from asset disposals in the previous year[8]. - The company confirmed government subsidies totaling CNY 81.9975 million, approximately 22.91% of the net profit attributable to shareholders for 2023[19]. - The company plans to repurchase shares with a total amount not less than CNY 40 million and not exceeding CNY 80 million, at a price not exceeding CNY 8 per share[17].